Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approval of update to the label of Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data – Supernus Pharma

Written by | 9 Feb 2025

Supernus Pharmaceuticals, Inc .announced that the FDA has approved an update for the label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data in Section 12.2. The… read more.

Adults diagnosed with ADHD may have reduced life expectancies

Written by | 1 Feb 2025

Adults who have been diagnosed with attention deficit hyperactivity disorder (ADHD) may be living shorter lives than they should, finds a world-first study led by UCL researchers. The… read more.

High doses of some prescription stimulants tied to increased psychosis risk

Written by | 20 Sep 2024

Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic. A… read more.

ADHD medications hit by supply shortages important to improve quality of life

Written by | 12 Aug 2024

Research led by the University of Southampton has found that medications play an important role in improving the quality of life of people with ADHD, but the authors… read more.

Sleep disorders in childhood increase ADHD risk

Written by | 7 Jul 2024

Epidemiologists in Spain have found a new link between childhood sleep patterns and behaviour, with implications for the understanding of attention deficit hyperactivity disorder (ADHD) in preadolescence. The… read more.

The FDA has approved Onyda XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD – Tris Pharma

Written by | 6 Jun 2024

Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, announced the FDA has approved Onyda XR (clonidine hydrochloride),… read more.

AI may aid in diagnosing adolescents with ADHD

Written by | 2 Dec 2023

Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers found significant differences in nine brain white matter tracts… read more.

Clinical trial demonstrates benefits of solriamfetol for adults with ADHD

Written by | 12 Oct 2023

Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical… read more.

Study shows nearly 300% increase in ADHD medication errors

Written by | 29 Sep 2023

Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million… read more.

‘Smart’ drugs can decrease productivity in people who don’t have ADHD, study finds

Written by | 20 Jun 2023

New research from the University of Cambridge and the University of Melbourne, published in Science Advances, shows neurotypical workers and students taking cognitive enhancers, or ‘smart’ drugs, may actually be… read more.

In some US schools, 1 in 4 students report misusing prescription stimulants

Written by | 27 Apr 2023

U.S. middle and high schools with the most students taking prescription stimulants to treat ADHD also had, overall, the highest percentage of students who misused prescription stimulants within… read more.

Blood pressure drug holds promise for treating PTSD

Written by | 6 Jan 2023

There is new evidence that a 50-year-old blood pressure drug could find new purpose as a treatment to mitigate the often life-altering effects of increasingly prevalent PTSD, scientists… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.